MOBIDIAG
22.4.2020 06:02:09 CEST | Business Wire | Press release
Mobidiag Ltd., a revenue generating, molecular diagnostics company with complementary platforms that address antimicrobial resistance and other areas of unmet diagnostic need, today announces that it has received emergency use authorization in Finland for its Novodiag® COVID-19 molecular diagnostic test for the rapid and fully automated detection of the SARS-CoV-2 virus, responsible for novel coronavirus infection (COVID-19). The Novodiag® COVID-19 is now available for use in Finland*. The process for obtaining emergency use authorization is now ongoing in Sweden, UK and France.
The Novodiag® COVID-19 assay allows qualitative determination of SARS-CoV-2 (orf1ab and N genes) directly from nasopharyngeal swabs. The test will operate using the Novodiag® rapid ‘sample-in, result-out’ system, allowing the fully automated detection of novel coronavirus in approximately 1 hour. In addition, Novodiag® has a closed system which ensures the protection of laboratory staff and healthcare professionals from possible contamination. The user-friendly nature of the system means that the Novodiag® system can also be used in high risk and hard to reach areas without the need for highly trained personnel.
This new test complements the emergency use test, Amplidiag® COVID-19 *, which is suitable for high-throughput screening, launched on 14 April 2020 . This test is now available in Finland and routinely used in the main Finnish clinical laboratories as well as in France where it has been validated by the National Center of Reference – Institut Pasteur.
Due to the high demand for diagnostic devices and tests globally, Mobidiag has ensured that its supply chain and manufacturing capabilities are robust and able to support its customers. This includes for example the sourcing and acquisition of various consumables to cover the complete workflow from sample collection to the results (e.g. inhouse production of enzymes, the development of our proprietary mNAT™ sample buffer and collection tubes).
Tuomas Tenkanen, CEO of Mobidiag, said, “The coronavirus pandemic is a global challenge that needs all parts of industry to respond with innovative solutions for multiple settings. Early detection of COVID-19 infections is critical in supporting clinical decisions to efficiently manage epidemiological and infection control measures to isolate patients in a timely manner and to globally improve patient care. At Mobidiag, we have harnessed our existing technologies and expertise, including supply chain management and manufacturing, to rapidly develop and supply two coronavirus diagnostics tests, providing clinicians solutions suited to their own laboratory capacities. We are pleased that from today we are able to offer Novodiag® COVID-19 which can be used in smaller units without the need for highly trained personnel and Amplidiag® COVID-19 which can be used in larger laboratories for high-throughput testing”.
* Amplidiag® COVID-19 is now available in Finland and France as an emergency use test. Novodiag® COVID-19 is available in Finland only at this time. Please note that Mobidiag tests are not home testing kits. They are only available for healthcare professionals, and not for patients directly. Please follow the recommended processes and guidance for your location if you believe you could be infected by SARS-CoV-2.
Notes to editors
About Mobidiag Ltd
Mobidiag is a commercial stage, fast growing molecular diagnostics company whose fast, cost-effective, widely applicable and robust technology makes the power of molecular diagnostics available to address the spread of infectious diseases and antimicrobial resistance (AMR) by rapid detection of pathogens and their potential resistance to antibiotics. Through its Amplidiag® and Novodiag® solutions, Mobidiag offers a comprehensive range of molecular diagnostic solutions for the detection of infectious diseases to laboratories of all sizes.
Mobidiag is headquartered in Espoo, Finland, with subsidiaries in France, UK and Sweden. To learn more, visit www.mobidiag.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20200421005945/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vonage and C3 AI Partner on Network-Enabled, Agentic AI Field Services Solution for Mobile Workforces11.2.2026 09:30:00 CET | Press release
Designed for mission-critical field operations, the joint solution combines autonomous and assisted AI with Vonage communications and network APIs for those working beyond the enterprise edge Vonage, part of Ericsson (NASDAQ: ERIC), today announced a strategic collaboration with C3 AI (NYSE: AI), a leading Enterprise AI application software provider, to launch C3 AI Field Services, a module of the C3 AI Asset Performance Suite of products, integrated with Vonage APIs. The AI-first module combines C3 AI’s powerful Enterprise AI capabilities with Vonage’s cutting-edge Communications APIs (Voice and Video) and Network APIs (Quality on Demand and Verify), to deliver superior performance, reliability and experiences for mobile enterprise field operations. This collaboration builds on a broader network-powered solutions offering from Vonage where application-aware networking, including advanced connectivity capabilities such as Quality on Demand (QoD), can be applied to support critical fiel
Mobileum and NOHOLD Launch White-Labeled AI Assistant Offering for Telecom Enterprise Customers11.2.2026 09:00:00 CET | Press release
First product release following the companies’ strategic AI alliance enables operators to monetize AI services for SME/SMBs through existing telco channels Mobileum Inc. (“Mobileum”), a leading global provider of analytics and network solutions, and NOHOLD, a leader in enterprise-grade AI assistant platforms, have announced the launch of a new white-labeled AI Assistant solution designed specifically for telecom operators serving small and medium-sized enterprises (SME/SMBs). The new offering builds on the strategic AI alliance announced in September 2025, moving from concept to a market-ready solution. Telecom operators can now offer branded AI Assistant services that help SME/SMBs enhance customer engagement, drive sales, and improve productivity through AI technology, with operators providing the tools so SME/SMBs avoid managing complex AI themselves. As traditional connectivity revenues continue to be under pressure, SME/SMBs are seeking value-added digital services from their tele
Merus Power leverer et energilagringssystem til ekstreme arktiske forhold11.2.2026 08:00:00 CET | Pressemeddelelse
Merus Power Oyj har indgået en aftale om levering af et batterienergilagringssystem til en værdi af cirka 13 mio. euro med Neve Oy. Anlægget på 30 MW/80 MWh er designet til at fungere under ekstremt kolde forhold og vil blive leveret til Rovaniemi ved udgangen af 2026. Virksomhederne har desuden indgået aftale om omfattende drifts- og vedligeholdelsestjenester for energilagringsanlægget. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20260205135896/da/ Merus Power delivered the first grid forming battery energy storage systems in the Nordics last year. The grid forming BESS to be deployed in Lapland is also designed to withstand extreme Arctic conditions. Energilagringsanlægget er konstrueret til at fungere pålideligt under arktiske forhold og kan modstå temperaturer helt ned til -50 °C samt kraftigt snefald og is. Systemet anvender grid forming-teknologi, som understøtter elnettets inerti og styrker stabiliteten i el-system
Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™11.2.2026 07:00:00 CET | Press release
Restylane® Refyne™ and Restylane Defyne™ are the first Optimal Balance Technology (OBT™) hyaluronic acid injectables ever approved and launched in Japan, bringing advanced flexibility and natural movement to the market1,2 This expands Galderma’s Restylane portfolio in Japan to four products, enabling treatment of a wider spectrum of patient and practitioner needs3,4 These two new launches underscore Galderma’s accelerating growth across the Japan & Asia Pacific (JPAC) region Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT‑based hyaluronic acid injectables ever authorized in Japan.1,2 The products – designed for injection into the mid-to-deep dermis for the correction of moderate to severe facial wrinkles and folds – are now commercially available in the market.1,2 Restylane Defyne and Refyne leverage the unique balance of softness, flexibility, and support delivered by Galderma’s proprieta
Suzano Reports Record Sales and Continued Improvements in Operational Efficiency in 202511.2.2026 00:44:00 CET | Press release
Suzano, the world’s largest pulp producer, announces its results for both the final quarter (4Q25) and the full year (2025), reporting record annual sales volumes and net revenue. The company also reported an improvement in its cash cost of pulp production, reflecting the drive for improved operational efficiency. Pulp and paper sales reached 14.2 million tonnes, a 15% increase compared to 2024. This performance was driven primarily by the strong operational contribution of the Ribas do Rio Pardo pulp mill, which began production in July 2024, and the company’s paper mills in the United States. As a result, Suzano’s full‑year net revenue reached a record R$50 billion in 2025. The company’s consistent focus on efficiency and cost discipline also contributed to a meaningful reduction in the cash cost of pulp production. Excluding downtime, the annual cash cost was R$817 per tonne, reaching its lowest annual level since 2021. Operational efficiency also helped Suzano deliver operating cas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom